KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Gross Margin (2022 - 2025)

Historic Gross Margin for Novavax (NVAX) over the last 11 years, with Q3 2025 value amounting to 69.49%.

  • Novavax's Gross Margin rose 412100.0% to 69.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.24%, marking a year-over-year increase of 275100.0%. This contributed to the annual value of 70.28% for FY2024, which is 52300.0% up from last year.
  • According to the latest figures from Q3 2025, Novavax's Gross Margin is 69.49%, which was up 412100.0% from 91.24% recorded in Q2 2025.
  • Novavax's Gross Margin's 5-year high stood at 100.0% during Q1 2021, with a 5-year trough of 45.8% in Q2 2022.
  • Moreover, its 5-year median value for Gross Margin was 69.49% (2025), whereas its average is 65.89%.
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -1458000bps in 2022, then soared by 1326600bps in 2023.
  • Novavax's Gross Margin (Quarter) stood at 100.0% in 2021, then crashed by -51bps to 49.14% in 2022, then fell by -5bps to 46.81% in 2023, then increased by 25bps to 58.48% in 2024, then grew by 19bps to 69.49% in 2025.
  • Its Gross Margin was 69.49% in Q3 2025, compared to 91.24% in Q2 2025 and 97.88% in Q1 2025.